Genentech recently won the patent for a psoriasis drug. Unfortunately, Roche’s Genentech unit prosecuted Eli Lilly for violation by claiming their psoriasis drugTalz, infringes on one of their patents.
Telemedicine services are gaining entry into Japanese hospitals. Royal Philips recently announced its deal with Showa University in Japan in order to launch the first telemedicine intensive care program (eICU) at Showa Koto Toyosu Hospital and Showa University Hospital. This program will reduce mortality rates and increase savings as well as case volume.
Johnson & Johnson has once again won in its appeals campaign against talcum powder verdicts. Last year, the company had secured two reversals. In this year, the Missouri Court of Appeals reversed another verdict in Gloria Ristesund’s case worth $55 million, where the court lacked jurisdiction.
Appthority, the mobile app security firm revealed that a security threat affecting more than 3,000 mobile apps exposes around 4 million protected health records such as prescription details and sensitive chat messages.
This Cardiogram work was based on Framingham Heart Study 2015, where the resting and variable heart rate significantly predicted hypertension and diabetes. This prototype helped the cardiogram research team to use the Apple Watch’s heart rate sensor for accurate diabetes predictions.
The latest in digital health news is that Amazon would be acquiring a virtual pharmacy named PillPack. Amazon’s website which is famous for online shopping is planning to expand by also including prescription medication.
Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million extension of series B funding led by Novo Holdings. Earlier in the series B funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.
Sanford Health, a healthcare delivery system acquired the Evangelical Lutheran Good Samaritan Society, a senior healthcare services provider for an undisclosed amount. Both South Dakota based healthcare providers announced the merge to form a $6 billion company with 47,000 employees nationwide.
To develop small molecules which can target RNA mis-splicing in neurological diseases, Celgene is launching a $60 million collaboration with Skyhawk Therapeutics. Celgene received the option to develop up to five drug molecules for correcting neurological diseases such as Huntington’s disease, amyotrophic lateral sclerosis etc. The $60 million payment includes milestones, license fees and royalties.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.